Analysts Set Cara Therapeutics, Inc. (NASDAQ:CARA) PT at $27.84

Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) have been given a consensus recommendation of “Hold” by the five research firms that are covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $27.84.

Separately, StockNews.com started coverage on shares of Cara Therapeutics in a research report on Wednesday, January 8th. They issued a “sell” rating on the stock.

Institutional Trading of Cara Therapeutics

A number of institutional investors have recently bought and sold shares of CARA. XTX Topco Ltd acquired a new stake in Cara Therapeutics in the 3rd quarter worth approximately $29,000. FMR LLC boosted its stake in Cara Therapeutics by 18.5% in the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 32,789 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN lifted its stake in Cara Therapeutics by 6.6% during the 2nd quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after acquiring an additional 120,660 shares during the period. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Cara Therapeutics Stock Down 10.2 %

Shares of Cara Therapeutics stock opened at $4.86 on Friday. The firm’s 50 day moving average price is $4.34 and its 200-day moving average price is $3.96. Cara Therapeutics has a 52-week low of $2.71 and a 52-week high of $13.80. The company has a market cap of $22.21 million, a P/E ratio of -0.23 and a beta of 0.51.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.